RPS6KA1 and cancer: Many cancer‐relevant signalling pathways were affected by OTS167; one example was the p90RSK pathway, with several activating sites of p90RSK and phosphorylation sites on three of its substrates, including an inhibitory phosphorylation site on the pro‐apoptotic protein BAD, showing clear reductions (Fig EV5A).